

February 04, 2026

To,

BSE Limited Corporate Relationship Dept., 1 st Floor, New Trading Ring, Rotunga Building, P.J. Towers, Dalal Street, Fort, Mumbai- 400001	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051
Scrip Code: 544292	Scrip Code: ONESOURCE

Dear Sir/Madam,

Sub: Disclosure Under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (the "Takeover Regulations")

Pursuant to Regulation 29(2) of the Takeover Regulations, kindly find enclosed herewith the disclosure in the prescribed format with respect to purchase of equity shares held by the promoter and promoter group.

Kindly take the same on record.

Thank you,

For Tenshi Pharmaceuticals Private Limited



Shridhara Kela

Director

DIN: 02592314

**Pranam, 1211 5th Cross Road, BDA Layout,
BTM 4th Stage 2nd Block, Near Electronic city RTO office,
Devarachikkanahalli, Bangalore Karnataka – 560076
February 04, 2026**



Copy to: Trisha A
Company Secretary and Compliance Officer
Unit No. 902, Cyber OnePlot No – 4 & 6,
Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane,
Thane, Maharashtra, India, 400703

Tenshi Pharmaceuticals Private Limited

**Registered Office: 'Karuna House' First Floor, Sy No 152/6 & 154/16, Dorasani palya, Begur Hobli,
Bannerghatta Road, Bengaluru-560076, Karnataka, India**

Tel.: +91 8029916826 | E-mail: secretarial@tenshi.co.in | CIN: U70200KA2016PTC200180

Format for Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Onesource Specialty Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Tenshi Pharmaceuticals Private Limited PAC: Karuna Business Solutions LLP Pronomz Ventures LLP Arco Lab Private Limited Arun Kumar Pillai Vineetha Mohanakumar Pillai Padmakumar Karunakaran Pillai Sajitha Pillai Rajitha Gopalakrishnan Aditya Arun Kumar Hemalatha Pillai		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	3,46,50,105	30.23	30.23
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)	3,46,50,105	30.23	30.23
Details of acquisition			
a) Shares carrying voting rights acquired	2,05,000	0.18	0.18
b) VRs acquired otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c+/-d)	2,05,000	0.18	0.18

Tenshi Pharmaceuticals Private Limited

Registered Office: 'Karuna House' First Floor, Sy No 152/6 & 154/16, Dorasani palya, Begur Hobli, Bannerghatta Road, Bengaluru-560076, Karnataka, India
 | Tel.: +91 8029916826 | E-mail: secretarial@tenshi.co.in | CIN: U70200KA2016PTC200180

After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	3,48,55,105	30.41	30.41
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c+d)	3,48,55,105	30.41	30.41
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Open Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Equity Shares		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	February 02, 2026		
Equity share capital / total voting capital of the TC before the said acquisition	11,46,21,201 equity shares of Rs. 1 each, fully paid up		
Equity share capital/ total voting capital of the TC after the said acquisition	11,46,21,201 equity shares of Rs. 1 each, fully paid up		
Total diluted share/voting capital of the TC after the said acquisition	11,46,21,201 equity shares of Rs. 1 each, fully paid up		

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For Tenshi Pharmaceuticals Private Limited

Signature of Director:


Shridhara Kela
 Director (DIN:02592314)



Place: Bangalore

Date: February 04, 2026